Wexford Capital’s Marker Therapeutics MRKR Stock Holding History

Wexford Capital’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,586	Closed	-$37K	–	288
2020 Q4	$37K	Buy	+2,586	New	+$40.1K	0.01%	278

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wexford Capital's MRKR Position: Q1 2021 in Review

Wexford Capital sold out of Marker Therapeutics (MRKR) in Q1 2021, closing a stake of 2,586 shares — an estimated $37K sold.

Wexford Capital first reported a position in MRKR in Q4 2020 and held it in 1 quarter. The position peaked at $37K in Q4 2020. 74 funds tracked by Wall St. Rank hold MRKR as of Q1 2021.

Wexford Capital reported no remaining Marker Therapeutics position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 2,586 Marker Therapeutics shares in Q1 2021, an estimated $37K.
Wexford Capital first reported a position in Marker Therapeutics in Q4 2020 and held it in 1 quarter.
Wexford Capital's Marker Therapeutics position peaked at $37K in Q4 2020.
74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.